《强生Johnson &ampamp Johnson（JNJ）2022年年度报告「NYSE」（英文版）（140页）.pdf》由会员分享，可在线阅读，更多相关《强生Johnson &ampamp Johnson（JNJ）2022年年度报告「NYSE」（英文版）（140页）.pdf（140页珍藏版）》请在三个皮匠报告上搜索。

1、Annual Report2022 was a year of achievement andevolution for Johnson&Johnson.We delivered solid financial performance and enhancedvalue for our shareholders.We made progress intwo significant undertakings:preparing Johnson&Johnson to operate as a faster,more focused two-sector company,and initiating

2、 the separation of ourConsumer Health business,Kenvue.We did all of this in a year when every industry felt the effects of highinflation,geopolitical tension,and continued supplychain disruption.Times like these remind me how privileged I am tolead Johnson&Johnson as the eighth Chairman and CEO in o

3、ur history.Our company has navigated through many economic cycles while addressing healthcares most important unmet needs for 137 years.Over that time,we have learned how to makedecisions for the long-term.Our deep commitment to Our Credo values,and determination to use our size for good,havelong ma

4、de us a global leader in health.Focusing on patient and customer needs reinforces our senseof purpose and urgency.Thanks to the 150,000 employees who embody these idealsand the breadth and diversification of our business2022was a successful year.Performance and PrioritiesIn 2022,we achieved full-yea

5、r operational salesgrowth of more than 6%*.Adjusted net earningswere$27 billion*and adjusted diluted net earningsper share were$10.15*,representing increases of 3.2%and 3.6%respectively,compared to 2021.Onan operational basis,adjusted diluted net earnings pershare increased by 9.2%*.We invested near

6、ly$15 billion in R&D,deployedmore than$17 billion toward acquisitions,increasedour dividend for the 60th consecutive year,andreturned capital to shareholders through our share repurchase program.Our total shareholder return(TSR)for 2022outperformed both our Competitor Composite and the S&P 500,contr